Phase I and, to a lesser extent, phase II clinical trials are in progress and are mainly recruiting pediatric patients with glioblastoma or different solid tumors that are treated with anti-PD1 drugs in combination with conventional therapies, radio-chemotherapies or surgery. Here, PDCD1 is linked to glioblastoma.